Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BioRestorative Therapies Inc BRTX

Healthcare Biotechnology
BioRestorative Therapies, Inc. is engaged in developing therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured... see more

Recent & Breaking News (NDAQ:BRTX)

BioRestorative Therapies' Drug Candidate BRTX-100 Passes Safety Test With Flying Colors, Moves Ahead With Phase 2 And Looks To Expand Pipeline Opportunities

Accesswire July 7, 2023

BioRestorative Therapies Receives Unanimous Recommendation from Data Safety Monitoring Board (DSMB) to Continue its Phase 2 Clinical Trial without any Changes

GlobeNewswire June 27, 2023

BioRestorative Therapies, Inc. to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET

GlobeNewswire June 16, 2023

Metabolic Syndrome: The Silent Epidemic On The Rise And How BioRestorative Therapies Inc. Is Helping Fight It

Accesswire June 15, 2023

BioRestorative Therapies Announces Key Milestone of Dosing Completion in Safety Cohort of Phase 2 Trial Targeting Chronic Lumbar Disc Disease

GlobeNewswire June 12, 2023

BioRestorative Therapies, Inc. to attend the Jefferies 2023 Healthcare Conference

GlobeNewswire June 1, 2023

BioRestorative Therapies Receives License from New York State Department of Health to act as Tissue Bank for Mesenchymal Stem Cell Processing

GlobeNewswire May 31, 2023

BioRestorative Therapies Receives Notice of Allowance by the Japanese Patent and Trademark Office for a Patent Application Related to its ThermoStem® Program

GlobeNewswire May 15, 2023

A New Era In Regenerative Medicine? BioRestorative Therapies (NASDAQ:BRTX) Reports Leading The Expansion Of The Adipose-Derived Stem Cell Therapy Market

Accesswire May 12, 2023

BioRestorative Therapies and Northwell Health Enter into Agreement to Participate in the Company's Phase 2 Clinical Trial

GlobeNewswire May 8, 2023

BioRestorative Therapies, Inc. to participate at the EF Hutton Global Conference May 10-11 in New York City

GlobeNewswire May 4, 2023

BioRestorative Therapies Announces Completion of Patient Enrollment for Safety Run-In Component of its Phase 2 Clinical Study of BRTX-100

GlobeNewswire April 24, 2023

BioRestorative Therapies (NASDAQ: BRTX) Is Targeting The Global Obesity Epidemic With Its Recent IP Portfolio Expansion

TheNewsWire March 31, 2023

What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?

TheNewsWire March 22, 2023

BioRestorative Therapies to Seek FDA Approval to Expand the Clinical Application of BRTX-100

GlobeNewswire March 13, 2023

BRTX’s ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome

TheNewsWire March 9, 2023

BioRestorative Therapies to Participate at the 35th Annual ROTH MKM Conference on March 12 -14, 2023

GlobeNewswire March 7, 2023

BioRestorative Therapies Receives Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its ThermoStem® Program

GlobeNewswire March 2, 2023

BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes

TheNewsWire February 10, 2023

BioRestorative Therapies Announces Notice of Allowance by the European Patent Office for Patent Related to its ThermoStem® Program

GlobeNewswire February 8, 2023